НидерландыChief Finance Officer
1 мес. назад
НидерландыC-levelHybrid
Senior executive responsible for overseeing the finance function at a global health tech company.
О компании
- is a global health tech company dedicated to breaking down barriers for patients seeking treatment options.
- We strive to enable earlier and better treatment access by bridging the gap between those searching for possible options, and the companies who develop them. We work closely with patients, healthcare professionals, trial sites, patient advocacy groups, and BioPharma – connecting key stakeholders in the drug development ecosystem.
- We’ve developed a cutting-edge AI-powered technology platform that simplifies and streamlines access to drugs in development. To support our users and clients, we have a range of industry-expert specialized teams ready to help. Our services include clinical trial patient recruitment, Expanded Access Program management and Real-World Data collection.
- With a global footprint spanning 134 countries, to date we’ve supported over 17,000 patients, 3,000 physicians and 350 sites, earning the trust of 60+ BioPharma companies. In October 2025, we closed a €25M investment with Avego Healthcare Capital to fuel our global ambitions and scale the business.
- Join us in shaping the future of treatment access - making tomorrow’s therapies accessible for people who need them today.
Требования
- Experience & Technical Depth
- Proven CFO or strong CFO-1 experience in a high-growth, investor-backed business, ideally in healthtech, healthcare services, life sciences, or another complex international platform environment.
- Buy-side M&A execution is a firm requirement . You have led acquisitions from the buyer's side, not only sell-side or advisory M&A, and can speak credibly to deal structuring, diligence, and post-deal integration.
- Multi-jurisdiction financial complexity : hands-on experience with transfer pricing, intercompany structures, and multi-party revenue recognition across at least two of the following: Europe, the US, and Asia.
- Institutional governance familiarity : direct experience with board reporting rhythms, supervisory board obligations, and the accountability that comes with a private equity or growth equity sponsor.
- Regulated sector navigation : exposure to compliance-intensive environments, ideally in healthcare, life sciences, or another highly regulated domain.
- Leading a lean senior team : you have led finance at this scale and know how to raise the ceiling of a small team rather than solving it with headcount.
- Fundraising and exit experience: you have run or closely supported a capital raise, whether equity, debt, or both, and ideally have direct exposure to a sale process, IPO, or other exit event. You know what "diligence-ready" actually means in practice.
Условия
- A Seat at the Table: Autonomy to shape the financial architecture of a category-defining company with deep strategic relevance.
- Stability + Speed: The financial backing of a leading healthcare investment fund, paired with the agility and creativity of a global scale-up.
- Comprehensive Executive Benefits: Competitive base salary, performance-driven annual bonus, and a substantial Employee Stock Option Plan (ESOP).
- Well-being & Development: Attractive pension plan (full premium covered by ), a dedicated personal learning budget, and mental health support via OpenUp.
- Our HQ Culture: Healthy lunches at our thriving headquarters, a hybrid working model, policies supporting working parents, and legendary events hosted by our Culture Club, including our annual "myTomorrowland" celebration.
Другое
- Every day, patients, physicians, and pharma companies navigate a fragmented, slow, and complex healthcare ecosystem to find pre-approval treatments. At , we are building the global infrastructure to solve this. Our mission is clear: to enable earlier and better access to all possible treatment options for patients who cannot afford to wait.
- Operating across 134+ countries, with hubs in Amsterdam, New York, and India, we've supported over 17,000 patients and 3,000+ physicians. Avego's €25 million growth investment is our launchpad to scale the business internationally, deepen BioPharma partnerships, and build the financial architecture that a company of this complexity now requires.
- As our Chief Financial Officer (CFO) , based at our Amsterdam headquarters, you will be a central member of the Leadership Team and a close strategic partner to the CEO. You will not simply run a finance function. You will build the financial infrastructure, governance, and discipline that this next chapter of growth demands, across a business spanning technology, regulated healthcare services, and multiple jurisdictions.
- As CFO, you will step into the trenches to tackle four defining challenges:
- Leading buy-side M&A execution: You will be the primary financial architect behind our inorganic growth. As evaluates acquisitions and strategic partnerships to complement organic growth, you will lead deal structuring, due diligence, valuation, and integration from a buyer's seat, bringing real process discipline to a company entering its first phase of consolidation.
- Architecting for multi-jurisdiction complexity: You will own the financial structure connecting our operations across the Netherlands, the US, and India. This means building robust transfer pricing policies, intercompany arrangements, and multi-party revenue recognition frameworks that hold up to investor and regulatory scrutiny as the business scales across borders.
- Being a credible investor partner: You will serve as the finance function's primary interface to our Supervisory Board. You will bring investor-grade reporting rhythms, board governance discipline, and the judgment to translate operational reality into the language our sponsor and Board expect.
- Preparing for future fundraising and exit: You will help set the company up for its next capital event, whether that is a follow-on raise, a strategic sale, or another form of exit. This means building the financial track record, audit readiness, and data room discipline that institutional buyers and investors expect, well ahead of any process actually starting.
- A Builder at Heart: You are energized by creating and scaling finance infrastructure, and you are comfortable reviewing a deal model, writing a Board memo, or rolling up your sleeves with the team when needed.
- Commercially Astute: You connect mission to economics, balancing patient-first principles with the discipline an investor-backed business requires, and you can challenge constructively.
- Low Ego, High Accountability: You establish clear standards, hold yourself and others to them, and proactively remove roadblocks rather than waiting for structure to be handed to you.
- A Strategic Connector: You translate financial complexity into a clear narrative for the CEO, Supervisory Board, and cross-functional leaders, building alignment and confidence in the numbers.
- Please note: this is a hybrid role, combining flexible home-office days with regular days at our Amsterdam headquarters. Because we value face-to-face collaboration during the week, we are looking for candidates who already live within commuting distance. We cannot provide fully remote options.
- You will inherit a finance function with a solid FP&A core and real scope to build:
- Structure: A multi-entity organization spanning the Netherlands, the US, and an operational hub in India, with growing cross-border complexity.
- Team: A lean, capable team of five. A finance lead as your direct report with three people behind her, plus Revenue Operations, giving you direct influence over pipeline, forecasting, and pricing rather than a view from the sidelines.
- Reporting: FP&A and performance reporting capability already in place; the priority now is professionalizing controls, governance, and investor-grade reporting infrastructure around it.
- Ownership: A Supervisory Board and a committed institutional sponsor, Avego Healthcare Capital, with clear expectations on growth economics, capital allocation, and value creation.
- Growth model: Organic growth complemented by inorganic opportunities, with M&A and strategic partnerships expected to play an increasing role in the company's next phase.
- When you look back at your first year and a half, you will have successfully:
- Led or materially advanced one or more buy-side M&A processes, demonstrating deal discipline from sourcing through integration.
- Established a robust multi-jurisdiction financial architecture, including transfer pricing policy and intercompany structures that hold up under scrutiny.
- Built investor-grade financial governance and greater confidence in data quality across the business.
- Strengthened the finance team and its standing with business leaders, while building on the FP&A foundation already in place.
- Become a trusted partner to the CEO and Supervisory Board, with a reporting rhythm that meets institutional ownership expectations.
- Helped shape a clear financial roadmap for international scale and long-term value creation.